Figures & data
Figure 1. Phenotypic features of bulk CIK cells. PBMCs from heathy individuals were exposed to IFN-γ, OKT3 and IL-2 for 3 weeks. (A) A representative experiment shows the phenotype of bulk CIK cells. (B) Average percentage of different cell subset in bulk CIK cells was measured by flow cytometry (n = 35).
Figure 2. Expression of NK-cell activating and inhibitory receptors on bulk CIK cells. (A) Cultured bulk CIK cells labeled with mAb recognizing NK activating receptors (NKG2D, NCRs) and inhibitory receptors (CD158a, CD158b). A representative experiment shows the different receptors on surface of bulk CIK cells. (B) Percentages of different receptors on bulk CIK cells were measured by flow cytometry (n = 35).
Table 1. Expression of NKG2D ligands and HLA class I on human myeloma cells and U266
Figure 3. NKG2D receptor was required for IFN-γ secretion. IFN-γ secretion was measured in bulk CIK cells by intracellular staining. (A) The represent experiment show IFN-γ secretion in NKG2D+ CIK cells after coculturing without or with U266 for 10 h. (B) U266 cells were treated with anti-MICA/B for 30 min then used for stimulating bulk CIK cells, compared with medium alone. *p < 0.05.C. IFN-γ concentrations in the culture supernatants were measured by ELISA. *p < 0.05.
Figure 4. NKG2D mediated CIK cells cytotoxicity against myeloma cells. (A) The gating strategy for the analysis of CIK-mediate cytotoxicity is shown in a representive experiment. The 7-AAD expression on CAM labeled U266 after incubation without or with bulk CIK cells for 10 h (E/T ratio = 10). (B) Cultuered bulk CIK cells were incubated in the presence of anti-NKG2D antibodies or medium alone for 30 min and then used for cytotoxicity assay against CAM labeled U266 compare with medium alone. *p < 0.05. (C) The cytotoxicity of cultured bulk CIK cells against primary MM cells derived from MM patient (patient 6) was assessed by flow cytometry.
